SCHEDULE: Sunshine Biopharma: Major Stakeholders Report Ownership Changes

Several investment entities and Michael Bigger have reported their beneficial ownership of Sunshine Biopharma Inc. common stock, with a combined stake of 9.47% as of May 18, 2025.

Summary

• This filing is a Schedule 13G, indicating that the reporting persons are passive investors who do not intend to influence or control the issuer.
• Bigger Capital Fund, LP and Bigger Capital Fund GP, LLC collectively beneficially own 805,000 shares of Sunshine Biopharma Inc. common stock, representing 4.73% of the outstanding shares.
• District 2 Capital Fund LP, District 2 Capital LP, District 2 GP LLC, and District 2 Holdings LLC collectively beneficially own 805,000 shares of common stock, also representing 4.73% of the outstanding shares.
• Michael Bigger, through his roles in the aforementioned entities, may be deemed to beneficially own a total of 1,610,000 shares, or approximately 9.47% of the outstanding common stock.
• The reported ownership figures as of May 18, 2025, do not include shares issuable upon the exercise of various warrants (Pre-Funded, Series B, and Series C) due to beneficial ownership limitations of 4.99% for each.
• As of May 19, 2026, the reporting persons have sold all of their common stock, including shares issuable upon exercise of Pre-Funded Warrants, and are no longer beneficial owners of at least 5.00% of the issuer's common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the complete divestment of significant stakes by the reporting persons shortly after the reporting date.

Positives

• The reporting persons hold a significant combined stake of 9.47% in Sunshine Biopharma Inc. as of May 18, 2025, indicating substantial investor interest.
• The filing confirms that the reporting persons are passive investors, which generally suggests they are not seeking to exert control over the company's management or operations.

Negatives

• The reporting persons have sold all of their shares as of May 19, 2026, indicating a complete divestment from Sunshine Biopharma Inc.
• The beneficial ownership limitations (4.99%) on warrants prevented the reporting persons from including a larger number of potential shares in their reported holdings.

Risks

• The beneficial ownership limitations on warrants could restrict future investment or influence if the company's stock price were to increase significantly.
• The complete sale of shares by these significant stakeholders as of May 19, 2026, could be interpreted as a lack of confidence in the company's future prospects by these investors.

Future Outlook

The filing indicates that as of May 19, 2026, the reporting persons have sold all of their shares and are no longer beneficial owners of at least 5.00% of the issuer's common stock. No forward-looking statements or guidance are provided regarding the company's future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and funds that acquire significant stakes in public companies but do not intend to control them. The reported ownership percentages and subsequent divestment by these entities provide insight into the shifting shareholder landscape for Sunshine Biopharma Inc.

Stakeholder Impact

• Shareholders may note the exit of significant investors, which could influence market perception.
• The complete sale of shares by Bigger Capital Fund and District 2 Capital entities suggests these investors no longer see value or strategic interest in holding Sunshine Biopharma Inc. stock.

Next Steps

• The reporting persons have completed their divestment of Sunshine Biopharma Inc. common stock.

Key Dates

Recommendation

The filing itself is a disclosure of ownership and divestment, not an operational or financial update. While the exit of significant investors warrants attention, it does not provide sufficient information to make a buy or sell recommendation without further context on Sunshine Biopharma's underlying business performance and prospects. Therefore, a 'hold' recommendation is appropriate pending more substantive information.

Keywords

Sunshine Biopharma Inc., Schedule 13G, Beneficial Ownership, Bigger Capital Fund, District 2 Capital Fund, Michael Bigger, Common Stock, Warrants, SEC Filing, Ownership Stake